{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T23:48:36Z","timestamp":1749685716560},"reference-count":41,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,10,15]]},"DOI":"10.2169\/internalmedicine.2982-19","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T18:03:43Z","timestamp":1561572223000},"page":"2969-2975","source":"Crossref","is-referenced-by-count":5,"title":["Ledipasvir and Sofosbuvir for Acute Hepatitis C Virus Monoinfection Associated with a High Risk of Acute Liver Failure"],"prefix":"10.2169","volume":"58","author":[{"given":"Takeshi","family":"Hatanaka","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Japan"},{"name":"Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Naganuma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumeo","family":"Tateyama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fukiko","family":"Yoshinari","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su Su","family":"Hmwe","sequence":"additional","affiliation":[{"name":"Department of Virology II, National Institute of Infectious Diseases, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Aizaki","sequence":"additional","affiliation":[{"name":"Department of Virology II, National Institute of Infectious Diseases, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaji","family":"Wakita","sequence":"additional","affiliation":[{"name":"Department of Virology II, National Institute of Infectious Diseases, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Kakizaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Uraoka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2: 161-176, 2017."},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Seeff LB. Natural history of chronic hepatitis C. Hepatology 36: S35-S46, 2002.","DOI":"10.1002\/hep.1840360706"},{"key":"3","unstructured":"3. Trey C, Davidson CS. The management of fulminant hepatic failure. Prog Liver Dis 3: 282-298, 1970."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137: 947-954, 2002.","DOI":"10.7326\/0003-4819-137-12-200212170-00007"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Schiodt FV, Davern TJ, Shakil AO, McGuire B, Samuel G, Lee WM. Viral hepatitis-related acute liver failure. Am J Gastroenterol 98: 448-453, 2003.","DOI":"10.1111\/j.1572-0241.2003.t01-1-07223.x"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 41: 1179-1197, 2005.","DOI":"10.1002\/hep.20703"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Inokuchi K, Nakata K, Hamasaki K, et al. Prevalence of hepatitis B or C virus infection in patients with fulminant viral hepatitis. An analysis using polymerase chain reaction. J Hepatol 24: 258-264, 1996.","DOI":"10.1016\/S0168-8278(96)80002-X"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kato T, Furusaka A, Miyamoto M, et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J Med Virol 64: 334-339, 2001.","DOI":"10.1002\/jmv.1055"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. AASLD\/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62: 932-954, 2015.","DOI":"10.1002\/hep.27950"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 69: 461-511, 2018.","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kalambokis G, Manousou P, Vibhakorn S, et al. Transjugular liver biopsy-indications, adequacy, quality of specimens, and complications-a systematic review. J Hepatol 47: 284-294, 2007.","DOI":"10.1016\/j.jhep.2007.05.001"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124: 91-96, 2003.","DOI":"10.1053\/gast.2003.50016"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Takikawa Y, Endo R, Suzuki K, Tsubouchi H. Early prediction of short-term development of hepatic encephalopathy in patients with acute liver disease unrelated to paracetamol. A prospective study in Japan. J Hepatol 51: 1021-1029, 2009.","DOI":"10.1016\/j.jhep.2009.09.011"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Wakita T. Isolation of JFH-1 strain and development of an HCV infection system. Methods Mol Biol 510: 305-327, 2009.","DOI":"10.1007\/978-1-59745-394-3_23"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Date T, Morikawa K, Tanaka Y, et al. Replication and infectivity of a novel genotype 1b hepatitis C virus clone. Microbiol Immunol 56: 308-317, 2012.","DOI":"10.1111\/j.1348-0421.2012.00437.x"},{"key":"16","unstructured":"16. Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: current status and remaining challenges. J Hepatol 49: 625-633, 2008."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Flamm SL, Yang YX, Singh S, Falck-Ytter YT. American Gastroenterological Association Institute Guidelines for the diagnosis and management of acute liver failure. Gastroenterology 152: 644-647, 2017.","DOI":"10.1053\/j.gastro.2016.12.026"},{"key":"18","unstructured":"18. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 13: 34-41, 2006."},{"key":"19","unstructured":"19. Wang CC, Krantz E, Klarquist J, et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis 196: 1474-1482, 2007."},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Grebely J, Page K, Sacks-Davis R, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 59: 109-120, 2014.","DOI":"10.1002\/hep.26639"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 139: 1586-1592, 1592.e1581, 2010.","DOI":"10.1053\/j.gastro.2010.07.005"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Thomson EC, Fleming VM, Main J, et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut 60: 837-845, 2011.","DOI":"10.1136\/gut.2010.217166"},{"key":"23","unstructured":"23. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. Jama 284: 450-456, 2000."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Rao HY, Sun DG, Jiang D, et al. IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat 19: 173-181, 2012.","DOI":"10.1111\/j.1365-2893.2011.01497.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Harris HE, Eldridge KP, Harbour S, Alexander G, Teo CG, Ramsay ME. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type? J Viral Hepat 14: 213-220, 2007.","DOI":"10.1111\/j.1365-2893.2006.00795.x"},{"key":"26","unstructured":"26. Martinello M, Gane E, Hellard M, et al. Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: the DARE-C II study. Hepatology 64: 1911-1921, 2016."},{"key":"27","unstructured":"27. Naggie S, Marks KM, Hughes M, et al. Sofosbuvir plus ribavirin without interferon for rreatment of acute hepatitis C virus infection in HIV-1-infected individuals: SWIFT-C. Clin Infect Dis 64: 1035-1042, 2017."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. El Sayed A, Barbati ZR, Turner SS, et al. Sofosbuvir in the treatment of early HCV infection in HIV-infected men. HIV Clin Trials 18: 60-66, 2017.","DOI":"10.1080\/15284336.2017.1280594"},{"key":"29","unstructured":"29. Basu PP, Shah NJ, Aloysius MM, Kavali L, Shehi E, Brown RS Jr. Sofosbuvir and ledipasvir versus sofosbuvir and simeprevir combination therapy in the management of acute hepatitis C: a randomized open label prospective clinical pilot study. Slam C Study. J Hepatol 64: S806, 2016."},{"key":"30","unstructured":"30. Deterding K, Spinner CD, Schott E, et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis 17: 215-222, 2017."},{"key":"31","unstructured":"31. Rockstroh JK, Bhagani S, Hyland RH, et al. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. Lancet Gastroenterol Hepatol 2: 347-353, 2017."},{"key":"32","unstructured":"32. Palaniswami PM, El Sayed A, Asriel B, Carollo JR, Fierer DS. Ledipasvir and sofosbuvir in the treatment of early hepatitis C virus infection in HIV-infected men. Open Forum Infect Dis 5: ofy238, 2018."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370: 1889-1898, 2014.","DOI":"10.1056\/NEJMoa1402454"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370: 1879-1888, 2014.","DOI":"10.1056\/NEJMoa1402355"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Donaldson BW, Gopinath R, Wanless IR, et al. The role of transjugular liver biopsy in fulminant liver failure: relation to other prognostic indicators. Hepatology 18: 1370-1376, 1993.","DOI":"10.1016\/0270-9139(93)90226-D"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Singhal A, Vadlamudi S, Stokes K, et al. Liver histology as predictor of outcome in patients with acute liver failure. Transpl Int 25: 658-662, 2012.","DOI":"10.1111\/j.1432-2277.2012.01470.x"},{"key":"37","unstructured":"37. Ware AJ, Jones RE, Shorey JW, Combes B. A controlled trial of steroid therapy in massive hepatic necrosis. Am J Gastroenterol 62: 130-133, 1974."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Gregory PB, Knauer CM, Kempson RL, Miller R. Steroid therapy in severe viral hepatitis. A double-blind, randomized trial of methyl-prednisolone versus placebo. N Engl J Med 294: 681-687, 1976.","DOI":"10.1056\/NEJM197603252941301"},{"key":"39","doi-asserted-by":"publisher","unstructured":"39. Karkhanis J, Verna EC, Chang MS, et al. Steroid use in acute liver failure. Hepatology 59: 612-621, 2014.","DOI":"10.1002\/hep.26678"},{"key":"40","unstructured":"40. Redeker AG, Schweitzer IL, Yamahiro HS. Letter: randomization of corticosteroid therapy in fulminant hepatitis. N Engl J Med 294: 728-729, 1976."},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Kakisaka K, Kataoka K, Suzuki Y, Kuroda H, Takikawa Y. Appropriate timing to start and optimal response evaluation of high-dose corticosteroid therapy for patients with acute liver failure. J Gastroenterol 52: 977-985, 2017.","DOI":"10.1007\/s00535-017-1306-5"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/20\/58_2982-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T23:34:37Z","timestamp":1571441677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/20\/58_2982-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":41,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2982-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]}}}